GlaxoSmithKline

GSK discontinues phase III HSV vaccine development after phase II trial failure. No safety concerns noted. GSK remains committed to innovative genital herpes treatments.

BioVersys secures $6m investment from GIBF2 for BV100 development in China, targeting CRAB infections. Phase 1 study to start in 1H 2025, leading to global Phase 3 trial.

GSK's phase II TH HSV REC-003 trial shows GSK3943104, an HSV vaccine candidate, did not meet primary efficacy objectives, halting progression to phase III. No safety concerns were observed, and the study will continue for safety monitoring and data collection on recurrent genital herpes. GSK aims to evaluate data for future HSV research.

Depemokimab, an ultra-long-acting biologic targeting IL-5, showed significant reduction in asthma exacerbations in 2 phase 3 trials (SWIFT-1 and SWIFT-2) for severe asthma with type 2 inflammation. The therapy met primary and key secondary endpoints, including reducing hospitalizations and emergency visits, though quality-of-life improvements were not statistically significant. Depemokimab, with 6-month dosing intervals, could be the first of its kind approved, offering potential benefits for severe asthma management.

GSK's Phase III trials of depemokimab in severe asthma showed a 54% reduction in exacerbations and a 72% reduction in hospitalisations. Safety profile was similar to placebo, with no related deaths or serious AEs.

GSK’s depemokimab, an ultra-long-acting biologic, significantly reduced severe asthma exacerbations by 54% over one year in phase 3 trials, with a 72% reduction in hospitalisations or emergency visits. Despite non-significant improvements in quality of life, the data supports global regulatory filings.

GSK's Phase III trials of depemokimab in severe asthma patients with elevated blood eosinophil counts showed a 54% reduction in exacerbations and a 72% reduction in hospitalisations or emergency visits. The treatment's safety profile was comparable to placebo.

GSK's ultra-long-acting biologic depemokimab, evaluated in Phase III trials for severe asthma, shows promise with two annual doses, reducing exacerbations and hospitalizations. It targets type 2 inflammation via high binding affinity for IL-5, with similar adverse event rates to placebo.